ONYX-015 genetically engineered adenovirus: Onyx began Phase I dose-escalation trials in head and neck cancer patients in the U.S. and U.K. ONYX-015 is a geneti

Onyx Pharmaceuticals, Richmond, Calif. Product: ONYX-015 genetically engineered adenovirus Indication: Head and neck cancer Status: Onyx began Phase I dose-escalation trials in head and neck cancer p...